A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia

Clinical Chemistry

Volumn 56, Issue 12, 2010, Pages 1862-1870

  Alloush, Habib M ^a,b   Anderson, Elizabeth ^a   Martin, Ashley D ^c   Ruddock, Mark W ^c   Angell, Johanna E ^a   Hill, Phil J ^d   Mehta, Priyanka ^e   Smith, M Ann ^f   Smith, J Graham ^g   Salisbury, Vyv C ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b HAIGAZIAN UNIVERSITY   (Lebanon)

^c Randox Laboratories Ltd   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; BIOLUMINESCENCE; BIOSENSOR; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; NONHUMAN; PREDICTION; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOSENSING TECHNIQUES; BONE MARROW CELLS; CELL LINE, TUMOR; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI; HUMANS; INTRACELLULAR SPACE; LEUKEMIA, MYELOID, ACUTE; LUMINESCENT MEASUREMENTS; MUTATION; NUCLEOSIDE DEAMINASES; PHOSPHORYLATION;

ARA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 78649822815     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.145581     Document Type: Article

References (24)

1. Hiddemann W, Buchner T. Current status and perspectives of therapies for acute myeloid leukaemia. Semin Hematol 2001;38:3-9.
2. Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000;18:3273-9.
3. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990;48:189-222.
4. Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009;77:1780-6.
5. Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008 68: 2349-57.
6. Jordheim L, Galmarini CM, Dumontet C. Drug resistance to cytotoxic nucleoside analogues. Curr Drug Targets 2003;4:443-60.
7. Smith MA, Smith JG, Pallister CJ, Singer CR. Haematopoietic growth, the cell cycle and sensitivity of AML cells to Ara-C. Leuk Lymphoma 1999;23:467-72.
8. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004;5:443-50.
9. Billard P, DuBow MS. Bioluminescence-based assays for detection and characterization of bacteria and chemicals in clinical laboratories. Clin Biochem 1998;31:1-14.
10. Michelini E, Magliulo M, Leskinen P, Virta M, Karp M, Roda A. Recombinant cell-based bioluminescence assay for androgen bioactivity determination in clinical samples. Clin Chem 2005;51: 1995-8.
11. Meighen EA. Bacterial bioluminescence: organization, regulation, and application of the lux genes. FASEB J 1993;7:1016-22.
12. Alloush HM, Lewis RJ, Salisbury VC. Bacterial bioluminescent biosensors for food and environmental monitoring: an overview. Anal Lett 2006; 39:1517-26.
13. Alloush HM, Salisbury VC, Lewis RJ, MacGowan AP. The pharmacodynamics of linezolid in a clinical strain of Streptococcus pneumoniae genetically modified to express lux genes. J Antimicrob Chemother 2002;52:511-3.
14. Beard SJ, Salisbury VC, Lewis RJ, Sharpe JA, MacGowan AP. Expression of lux genes in a clinical isolate of Streptococcus pneumoniae: using bioluminescence to monitor gemifloxacin activity. Antimicrob Agents Chemother 2002;46: 538-42.
15. Wang J, Neuhard J, Eriksson S. An Escherichia coli system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs. Antimicrob Agents Chemother 1998;42:2620-5.
16. Jensen KF. The Escherichia coli K-12 "wild types" W3110 and MG1655 have an rph frameshift mutation that leads to pyrimidine starvation due to low pyrE expression levels. J Bact 1993;175: 3401-7.
17. Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, Roop RM, Peterson KM. Four new derivatives of broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 1994;166:800-2.
18. Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia 1998; 12:S16-9.
19. Miller JH. Experiments in molecular genetics. New York: Cold Spring Harbor Laboratory; 1972.
20. Galluzzi L, Karp M. Intracellular redox equilibrium and growth phase affect the performance of luciferase-based biosensors. J Biotech 2007;127: 188-98.
21. Cutter KL, Alloush HM, Salisbury VC. Stimulation of DNA repair and increased light output in response to UV irradiation in Escherichia coli expressing lux genes. Luminescence 2006;22:177-81.
22. Kozakiewicz J, Gajewska M, Lyzeń R, Czyz A, Wegrzyn G. Bioluminescence-mediated stimulation of photoreactivation in bacteria. FEMS Microbiol Lett 2005;250:105-10.
23. Czyz A, Plata K, Wegrzyn G. Induction of light emission by luminescent bacteria treated with UV light and chemical mutagens. J Appl Genet 2002; 43:377-89. (Pubitemid 135705675)
24. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin 2005;55:74-108.